On the use of familial aggregation in population-based case probands for calculating penetrance
- PMID: 12189225
- DOI: 10.1093/jnci/94.16.1221
On the use of familial aggregation in population-based case probands for calculating penetrance
Abstract
Background: Estimating the lifetime risk associated with (i.e., the penetrance of) genetic abnormalities that predispose individuals to cancer is important for genetic counseling. (Penetrance may be estimated from the degree of familial aggregation of cancer, that is, the extent to which cancers cluster in families.) Early penetrance studies of BRCA1 and BRCA2 mutations used high-risk families with multiple cases of breast cancer, a study design that led to very high penetrance estimates. However, such studies were subject to potential ascertainment biases. To offset such biases, recent studies have used data from family members of probands ascertained from population-based incident cases of cancer. The use of case probands is, however, also subject to bias because all risk factors are over-represented in case patients. To draw attention to this problem, literature on the penetrance of breast cancer in BRCA1 and BRCA2 carriers is reviewed.
Methods: A theory is presented to show that the use of case probands is itself biased, leading to inflated penetrance estimates. The strategy is unbiased only if all carriers share an identical risk. Any unexplained heterogeneity of risk caused by unknown genetic or shared environmental factors within families leads to an inflated estimate of penetrance.
Results: Eight published studies using population-based methods are reviewed. All but one of the family-based studies used case probands.
Conclusions: Penetrance estimates from case proband studies must be inflated if other factors influence breast cancer risk in addition to the specific genetic abnormality. Thus, women with such genetic abnormalities and a strong family history of breast cancer are likely to possess a much higher risk for breast cancer than women with such abnormalities but without a strong family history. Methodologic techniques to improve the prediction of cancer risk are needed.
Comment in
-
Genetic risk in context: calculating the penetrance of BRCA1 and BRCA2 mutations.J Natl Cancer Inst. 2002 Aug 21;94(16):1185-7. doi: 10.1093/jnci/94.16.1185. J Natl Cancer Inst. 2002. PMID: 12189215 No abstract available.
-
Re: On the use of familial aggregation in population-based case probands for calculating penetrance.J Natl Cancer Inst. 2003 Jan 1;95(1):73-4; author reply 77-8. doi: 10.1093/jnci/95.1.73-a. J Natl Cancer Inst. 2003. PMID: 12509405 No abstract available.
-
Re: On the use of familial aggregation in population-based case probands for calculating penetrance.J Natl Cancer Inst. 2003 Jan 1;95(1):74-5; author reply 77-8. doi: 10.1093/jnci/95.1.74. J Natl Cancer Inst. 2003. PMID: 12509406 No abstract available.
-
Re: On the use of familial aggregation in population-based case probands for calculating penetrance.J Natl Cancer Inst. 2003 Jan 1;95(1):75-6; author reply 77-8. doi: 10.1093/jnci/95.1.75. J Natl Cancer Inst. 2003. PMID: 12509407 No abstract available.
-
Re: On the use of familial aggregation in population-based case probands for calculating penetrance.J Natl Cancer Inst. 2003 Jan 1;95(1):76-7; author reply 77-8. doi: 10.1093/jnci/95.1.76. J Natl Cancer Inst. 2003. PMID: 12509408 No abstract available.
-
Re: On the use of familial aggregation in population-based case probands for calculating penetrance.J Natl Cancer Inst. 2003 Jan 1;95(1):78-9. doi: 10.1093/jnci/95.1.78. J Natl Cancer Inst. 2003. PMID: 12509410 No abstract available.
Similar articles
-
Optimal designs for estimating penetrance of rare mutations of a disease-susceptibility gene.Genet Epidemiol. 2003 Apr;24(3):173-80. doi: 10.1002/gepi.10219. Genet Epidemiol. 2003. PMID: 12652521
-
Population-based study of changing breast cancer risk in Icelandic BRCA2 mutation carriers, 1920-2000.J Natl Cancer Inst. 2006 Jan 18;98(2):116-22. doi: 10.1093/jnci/djj012. J Natl Cancer Inst. 2006. PMID: 16418514
-
Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.Clin Cancer Res. 2002 Dec;8(12):3776-81. Clin Cancer Res. 2002. PMID: 12473589
-
Genetic Tests for Breast and Ovarian Cancer [Internet].Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2008 Feb. Report from Norwegian Knowledge Centre for the Health Services (NOKC) No. 05-2008. Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2008 Feb. Report from Norwegian Knowledge Centre for the Health Services (NOKC) No. 05-2008. PMID: 29319983 Free Books & Documents. Review.
-
[Clinical and molecular diagnosis of inherited breast-ovarian cancer].J Gynecol Obstet Biol Reprod (Paris). 2003 Apr;32(2):101-19. J Gynecol Obstet Biol Reprod (Paris). 2003. PMID: 12717301 Review. French.
Cited by
-
LGI1 mutations in autosomal dominant partial epilepsy with auditory features.Neurology. 2004 Apr 13;62(7):1120-6. doi: 10.1212/01.wnl.0000120098.39231.6e. Neurology. 2004. PMID: 15079011 Free PMC article.
-
Pregnancies, breast-feeding, and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS).J Natl Cancer Inst. 2006 Apr 19;98(8):535-44. doi: 10.1093/jnci/djj132. J Natl Cancer Inst. 2006. PMID: 16622123 Free PMC article.
-
Cancer risks among BRCA1 and BRCA2 mutation carriers.Br J Cancer. 2007 Jan 15;96(1):11-5. doi: 10.1038/sj.bjc.6603535. Br J Cancer. 2007. PMID: 17213823 Free PMC article. Review.
-
Risk of Parkinson disease in carriers of parkin mutations: estimation using the kin-cohort method.Arch Neurol. 2008 Apr;65(4):467-74. doi: 10.1001/archneur.65.4.467. Arch Neurol. 2008. PMID: 18413468 Free PMC article.
-
Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis.J Natl Cancer Inst. 2014 Jun;106(6):dju091. doi: 10.1093/jnci/dju091. J Natl Cancer Inst. 2014. PMID: 24824314 Free PMC article. Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous